Additional European Equity News
AstraZeneca (AZN LN) - Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy. Elsewhere Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD). (AstraZeneca)
Atos (ATO FP) - US Court of Appeals has issued a favourable decision for Atos in the Trizetto litigation. (Newswires)
Credit Suisse (CSGN SW) - Co. has lost the Singapore case with a billionaire over fraud. (Newswires)
Frasers (FRAS LN) - Put options sold by Ashley have been exercised and settled. (Frasers)
26 May 2023 - 07:30- EquitiesEU Research- Source: Newsquawk
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts